CONVERT PHARMACEUTICALS: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CONVERT PHARMACEUTICALS
Largest movements
- Cash -€393,331
down €393,331 (-71.3%), from €551,649 to €158,318
mainly Net result for the year (-€629,343) and Debts after one year (-€562,891)
- Intangible fixed assets +€112,893
up €112,893 (+17.3%), from €652,282 to €765,176
- Contributions +€952,497
up €952,497 (+62.7%), from €1.5m to €2.5m
of which Capital: +€952,497
- Profit (loss) carried forward -€629,343
down €629,343 (-17.6%), from -€3.6m to -€4.2m
- Debts after one year -€562,891
down €562,891 (-27.2%), from €2.1m to €1.5m
- Accrued charges and deferred income -€259,001
no longer reported in 2025 (was €259,001)
- Trade debts +€223,488
up €223,488 (+412%), from €54,209 to €277,698
- Gross operating margin +€266,022
up €266,022 (+51.8%), from -€513,906 to -€247,884
- Purchases and services +€248,532
new in 2025: €248,532
- Financial income -€229,013
down €229,013 (-99.7%), from €229,648 to €636
- Depreciation +€77,519
up €77,519 (+34.7%), from €223,509 to €301,029
- Taxes -€69,593
down €69,593 (-66.7%), from €104,373 to €34,780
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,216,454 | €941,204 | -€275,250 | -22.6% |
| Fixed assets | 21/28 | €652,282 | €765,176 | +€112,893 | +17.3% |
| Intangible fixed assets | 21 | €652,282 | €765,176 | +€112,893 | +17.3% |
| Current assets | 29/58 | €564,171 | €176,028 | -€388,143 | -68.8% |
| Amounts receivable within one year | 40/41 | €12,522 | €17,710 | +€5,188 | +41.4% |
| Other amounts receivable | 41 | €12,522 | €17,710 | +€5,188 | +41.4% |
| Cash at bank and in hand | 54/58 | €551,649 | €158,318 | -€393,331 | -71.3% |
| Total equity and liabilities | 10/49 | €1,216,454 | €941,204 | -€275,250 | -22.6% |
| Equity | 10/15 | -€1,164,977 | -€841,823 | +€323,154 | +27.7% |
| Contributions | 10/11 | €1,520,186 | €2,472,683 | +€952,497 | +62.7% |
| Capital | 10 | €1,270,186 | €2,222,683 | +€952,497 | +75.0% |
| Issued capital | 100 | €1,270,186 | €2,222,683 | +€952,497 | +75.0% |
| Contributions outside capital | 11 | €250,000 | €250,000 | = | 0.0% |
| Share premium | 1100/10 | €250,000 | €250,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€3,580,515 | -€4,209,858 | -€629,343 | -17.6% |
| Investment grants | 15 | €895,352 | €895,352 | = | 0.0% |
| Amounts payable | 17/49 | €2,381,431 | €1,783,027 | -€598,404 | -25.1% |
| Amounts payable after more than one year | 17 | €2,068,221 | €1,505,330 | -€562,891 | -27.2% |
| Financial debts | 170/4 | €2,068,221 | €1,505,330 | -€562,891 | -27.2% |
| Amounts payable within one year | 42/48 | €54,209 | €277,698 | +€223,488 | +412% |
| Trade debts | 44 | €54,209 | €277,698 | +€223,488 | +412% |
| Suppliers | 440/4 | €54,209 | €277,698 | +€223,488 | +412% |
| Accrued charges and deferred income | 492/3 | €259,001 | - | -€259,001 | |
| Non-recurring operating income | 76A | - | €648 | +€648 | |
| Goods, raw materials, services and sundry goods | 60/61 | - | €248,532 | +€248,532 | |
| Remuneration, social security and pensions | 62 | €3,549 | - | -€3,549 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €223,509 | €301,029 | +€77,519 | +34.7% |
| Other operating charges | 640/8 | €220 | €220 | = | 0.0% |
| Gross operating margin | 9900 | -€513,906 | -€247,884 | +€266,022 | +51.8% |
| Operating profit (loss) | 9901 | -€741,184 | -€549,133 | +€192,051 | +25.9% |
| Financial income | 75/76B | €229,648 | €636 | -€229,013 | -99.7% |
| Recurring financial income | 75 | €229,648 | €636 | -€229,013 | -99.7% |
| Financial charges | 65/66B | €29,910 | €46,065 | +€16,156 | +54.0% |
| Recurring financial charges | 65 | €29,910 | €46,065 | +€16,156 | +54.0% |
| Profit (loss) for the period before taxes | 9903 | -€541,445 | -€594,563 | -€53,117 | -9.8% |
| Income taxes | 67/77 | €104,373 | €34,780 | -€69,593 | -66.7% |
| Profit (loss) for the period | 9904 | -€645,819 | -€629,343 | +€16,476 | +2.6% |
| Profit (loss) for the period to be appropriated | 9905 | -€645,819 | -€629,343 | +€16,476 | +2.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 15 October 2026 via checked.be.